Skip to main content
. 2024 Feb 29;13(3):228. doi: 10.3390/antibiotics13030228

Figure 3.

Figure 3

The stability of NZ2114 and NZ2114-NPs under different physiological conditions. (AC) Peptide retention of NZ2114 and NZ2114-NPs at serum concentrations of 50%, 25% and 12.5%, respectively. (D) Effects of pepsin and trypsin on the antimicrobial activity of NZ2114 and NZ2114-NPs against S. epidermidis G4. NZ2114-NPs: PLGA-encapsulated NZ2114 (formulation-13). Results are given as mean ± SD (n = 3).